$SPRC News

SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation Covering SCI-110

SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

SciSparc Says NeuroThera Labs Advances Participant Enrollment For Clinical Trial Assessing SCI-210 Treatment For Symptoms Associated With Autism Spectrum Disorder

SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board

SciSparc Adds Prof. Carmel Domshlak To Newly Established Scientific Advisory Board For AI And Cybersecurity, Effective September 1

SciSparc Unit Neurothera Labs And Clearmind Medicine Publish U.S. Patent Application For A Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines For Use In Methods Of Treating Post-Traumatic Stress Disorder, Anxiety And Eating Disorders

SciSparc shares are trading higher. The company announced its majority-owned subsidiary, NeuroThera Labs, has completed two tranches of non-brokered private placements, raising aggregate gross proceeds of C$5.4 million.

SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million

SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination

SciSparc Unit Neurothera Labs Receives Japanese Patent For Its Pharmacological Combination Titled 'Compositions And Methods For Potentiating Derivatives Of 4-Aminophenols'

SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome

SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics

What's Going On With SciSparc Shares On Friday?

SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company

SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity

NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

SciSparc Subsidiary NeuroThera Labs Completes Acquisition Of ~54% Stake In CliniQuantum

NeuroThera Labs Inc. Announces Closing of Acquisition of Majority Stake in CliniQuantum Ltd.